Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
AstraZeneca
McKesson
Federal Trade Commission
Cerilliant
UBS
Johnson and Johnson
Merck

Generated: June 17, 2018

DrugPatentWatch Database Preview

CLEVIPREX Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Cleviprex patents expire, and what generic alternatives are available?

Cleviprex is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-two patent family members in thirty-three countries.

The generic ingredient in CLEVIPREX is clevidipine. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clevidipine profile page.
Summary for CLEVIPREX
International Patents:62
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 66
Clinical Trials: 11
Patent Applications: 489
DailyMed Link:CLEVIPREX at DailyMed
Drug patent expirations by year for CLEVIPREX
Pharmacology for CLEVIPREX
Synonyms for CLEVIPREX
(Butanoyloxy)methyl methyl (4RS)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate"
166432-28-6
167221-71-8
221C718
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarb
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
3-[(Butyryloxy)methyl] 5-Methyl 4-(2,3-Dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester
4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid 3-Methyl 5-[(1-Oxobutoxy)methyl] Ester
4-(2,3-Dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic Aicd 3-[(Butyryloxy)methyl] 5-Methyl Ester
5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
AB01566888_01
AB2000484
ABP001090
AC-24370
AC1L4BI0
AK163183
AKOS015896325
AMX10159
AN-16754
AS-19935
BDBM50088387
Butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylat
butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
C21H23Cl2NO6
C3503
CAS-167221-71-8
CC0258
CHEBI:135738
CHEMBL1237132
Clevelox
Clevidipine
Clevidipine (USAN/INN)
Clevidipine [USAN:INN]
Clevidipine butyrate
Clevidipine, Cleviprex
Clevidipine; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate
Cleviprex (TN)
CS-1427
CTK4D2578
D08892
DB04920
DSSTox_CID_31450
DSSTox_GSID_57661
DSSTox_RID_97336
DTXSID6057661
FT-0659562
FT-0688416
GTPL7468
H 324/38
H-324/38
H324/38
HE317022
HMS3604H21
HMS3651G10
HY-17436
I06-2062
I14-17270
J-520103
KB-53558
KPBZROQVTHLCDU-UHFFFAOYSA-N
KS-00000XIM
MCULE-6863602192
Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate
Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3-CARBOXYLATE
MolPort-020-006-047
NCGC00262928-01
O3-(butanoyloxymethyl) O5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
O5-(butanoyloxymethyl) O3-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
OR074104
rac-Clevidipine
RL02144
s2080
SCHEMBL115522
SR-01000945183
SR-01000945183-1
SR-01000945183-2
Tox21_113923
W-5232
Z1691545244
Z1845

US Patents and Regulatory Information for CLEVIPREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for CLEVIPREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for CLEVIPREX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/011 United Kingdom ➤ Sign Up PRODUCT NAME: CLEVIDIPINE; REGISTERED: UK PL16881/0003 20111123
209 Luxembourg ➤ Sign Up PRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
90008-0 Sweden ➤ Sign Up PRODUCT NAME: CLEVIDIPINE; NAT. REG. NO/DATE: 42321 20120120; FIRST REG.: GB PL 16881/0003 20111123
0726894/01 Switzerland ➤ Sign Up PRODUCT NAME: RACEMISCHES CLEVIDIPINBUTYRAT; REGISTRATION NO/DATE: SWISSMEDIC 60117 11.06.2010
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Deloitte
Argus Health
Boehringer Ingelheim
UBS
Federal Trade Commission
Queensland Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.